Overview

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions

Status:
Completed
Trial end date:
1998-01-01
Target enrollment:
Participant gender:
Summary
To compare the relative bioavailability of gabapentin 400 mg capsules (Purepac) with that of NEURONTIN® 400 mg capsules (Parke-Davis) in healthy adult male subjects under non-fasting conditions, and to compare the differences in plasma levels after dosing the test formulation with and without food
Phase:
Phase 1
Details
Lead Sponsor:
Actavis Inc.
Treatments:
Gabapentin
gamma-Aminobutyric Acid